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Pharmaceutical careAbstract Background:Highly active antiretroviral therapy (HAART) is complex and many factors
contribute to a patient’s response to initial therapy including adherence, drug effectiveness, and tol-
erance. Close HAART follow-up is needed, particularly when there are concurrent therapies such as
prophylactic antibiotics and medications for the treatment of comorbidities. Objective: To assess the
effectiveness of pharmacist intervention in reducing drug related problems in HIV/AIDS outpa-
tients (intervention group) and in improving clinical parameters in the intervention group compared
to the control group. Methods: We conducted a prospective controlled intervention study with
patients paired by gender and initial T CD4+ lymphocyte (CD4) count. HIV-infected patients
of a public outpatient service were enrolled for the study by consecutive and convenience sampling.
Patients selected for the study were divided into a control group and an intervention group. Both
groups were followed for one year; however, only the intervention group received pharmaceutical
care. The primary outcome was the drug related problem (DRP) analysis for the intervention group.
Secondary outcomes were CD4 count and viral load evaluation for both groups. Results: There was
a total of 143 patients enrolled in this study, with 53 (37.06%) patients in the control group and 90
(62.94%) patients in the intervention group. A total of 202 pharmacist interventions with 193
pharmacist-patient and 9 pharmacist-physician interventions were proposed. After one year of
pharmaceutical care, a reduction of 38.43% between the initial and final DRP was foundg-related
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problems. Saudi Pharmaceutical Journal (20(p= 0.0001). The most common DRPs found were related to medication safety. The intervention
group showed a mean increase of 84% for the CD4 count in comparison with that observed in the
control group. The viral load was not significantly different between the final and initial mean val-
ues for both groups. Conclusion: Pharmacist appointments enabled identification, prevention, and
solving of drug related problems, especially those related to drug safety. Also, pharmacist interven-
tions improved adherence and increased HAART effectiveness as suggested by the higher elevation
in the CD4 count seen in the intervention group in comparison with the control group.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In Brazil, from 1980 to June 2014, 757,042 cases of Acquired
Immunodeficiency Syndrome (AIDS) were reported, of which
411,800 (54.4%) of the cases were reported in the southeast of
Brazil (Brazil. Ministry of Health., 2014). Among those, 15,768
were new AIDS cases in 2014, with a national incidence rate of
20.4/100,000 individuals with AIDS reported in 2013 (Brazil.
Ministry of Health., 2014). Although Brazil provides free ther-
apy to treat against Human Immunodeficiency Virus (HIV),
access to pharmaceutical care for people living with HIV/
AIDS is a major challenge for public health systems, especially
in developing countries (Oliveira et al., 2002; Remondi et al.,
2014).
The goal of highly active antiretroviral therapy (HAART)
is to achieve maximum suppression of HIV replication, result-
ing in an increased immune response. However, HAART is
not effective unless patients are committed and able to adhere
to the treatment regimen. In addition, health care professionals
must be able to manage the therapy. Non-adherence or partial
adherence to HAART can lead to virologic failure, develop-
ment of viral resistance to antiretroviral drugs, and death
(Bezabhe et al., 2016).
HAART is complex and many factors contribute to a
patient’s response to initial therapy including adherence, drug
effectiveness, and tolerance (Bolsewicz et al., 2015; Henderson
et al., 2011; Verdugo et al., 2007). Furthermore, drug related
problems (DRPs) are frequently found in HIV/AIDS patients.
DPRs mainly occur due to drug-drug and drug-food interac-
tions, adverse drug reactions, drug omission or unnecessary
prescribed drug, no dosage adjustment in patients with renal
or hepatic impairment, errors in drug indication, dosing, regi-
men and scheduling (Carcelero et al., 2011; Li and Foisy, 2014;
Molino et al., 2014; Ojeh et al., 2015).
Drug interaction is commonly found between HAART,
HAART and other drugs used to treat comorbidities, and
HAART and food (Hughes et al., 2015; Ojeh et al., 2015;
Rathbun and Liedtke, 2011). Antiretroviral drugs that func-
tion as protease inhibitors are extensively metabolized by the
cytochrome P450. The concomitant use of these drugs and
others also metabolized by CYP P450 can result in drug inter-
action (Hughes et al., 2015; Rathbun and Liedtke, 2011).
Drugs with narrow therapeutic index and metabolized by
CYP450, such as warfarin, require close monitoring when used
with HAART (Esterly et al., 2013).
Besides some of the well-known mechanisms of drug inter-
actions causing side effects, medications often present adverse
effects leading to treatment discontinuation (Hughes et al.,
2015; Rathbun and Liedtke, 2011; Verdugo et al., 2007,.R.C. et al., HIV pharmaceutical care i
16), http://dx.doi.org/10.1016/j.jsps.2012010). A multi-center study conducted in Spain found that a
quarter of HIV patients had discontinued tenofovir treatment
due to adverse drug effects (Verdugo et al., 2007). Also, the
risk of virologic failure commonly associated with antiretrovi-
ral resistance increases when compliance decreases (Bezabhe
et al., 2016; Pirkle et al., 2009). Close HAART follow-up is
needed, particularly when there are concurrent therapies such
as prophylactic antibiotics and medications for the treatment
of comorbidities. Studies have shown a significant decrease
in medication errors in institutions where pharmacists perform
interventions with a team of clinicians. These studies support
the fact that pharmacist intervention can reduce the number
of adverse events, improve quality of health care, and minimize
hospital costs (Carnevale et al., 2015; Chisholm-Burns et al.,
2010; De Rijdt et al., 2008; Kaboli et al., 2006; Kopp et al.,
2007; Stark et al., 2011).
1.1. Aim of the study
Pharmaceutical care encourages patients to be familiar with
their own regimens, making it easier to understand the impor-
tance of drug adherence, as well as increasing therapy adher-
ence, effectiveness, and tolerance. The aim of this study was
to evaluate the effectiveness of pharmacist intervention in
reducing drug related problems in the HIV/AIDS outpatients
(intervention group) and in improving clinical parameters in
the intervention group compared to the control group.2. Methods
2.1. Design and setting
This study was performed at the Hospital Dia-University of
Campinas Teaching Hospital, Campinas, Brazil, from January
2009 to June 2012.
We conducted a prospective controlled intervention study
with patients paired by gender and initial T CD4+ lympho-
cyte (CD4) count. First, the clinical pharmacy staff analyzed
all medical charts available during medical appointments in
Hospital Dia to check whether patients fit the study criteria.
Then, those who fit these criteria were assigned to Control/
Intervention Group through a convenience sample. Both
groups were followed for one year; however, only the interven-
tion group received pharmaceutical care.
Each patient from the control group was matched with a
patient from the intervention group according to their baseline
CD4 count, considering a maximum variation range of 10%
between their CD4 counts. Since the control group consistedn primary healthcare: Improvement in CD4 count and reduction in drug-related
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with a control patient and compare the outcomes.
Laboratory specimens were collected in the morning and
subsequent analysis was carried out by a laboratory at the
University of Campinas Teaching Hospital.
2.2. Subjects
HIV/AIDS outpatients from the Hospital Dia were eligible to
participate in our study if they were between 18 and 65 years of
age, with a body mass index of <30 kg/m2 and were undergo-
ing HAART. Elderly patients (>65 years old) were excluded
since it is known that elderly individuals present with more
comorbidities; thus, their pharmacotherapy is more complex
and associated with a greater number of drug interactions,
adverse reactions, and toxicity (Hasse et al., 2011). Further-
more, previous data have shown that higher HIV infection
progression and mortality rates have been identified among
older patients compared with younger patients (Nguyen and
Holodniy, 2008). Obese patients were also excluded since they
present with higher incidences of hyperlipidemia and the fact
that some HIV medications, such as protease inhibitors, are
associated with weight gain and fat accumulation (Bavinger
et al., 2013; Crum-Cianflone et al., 2010; Dube, 2000; Friis-
Møller et al., 2003; Hasse et al., 2011).
Patients were excluded if they were homeless or prisoners,
had severe psychiatric disease that limited their comprehen-
sion, did not follow up on previously scheduled appointments,
refused to participate in the study, got pregnant, attended
fewer than two pharmacist appointments, had pharmacist
appointments at an interval greater than 6 months, did not
complete one year of pharmaceutical care, were switched to
another health service, or missed their appointments with their
physician.
2.3. Pharmaceutical care service
A clinical pharmacy team analyzed patients’ medical charts to
ensure they fit with the study criteria. Those who were eligible
were assigned to an intervention or control group depending
on the clinical pharmacist’s appointment schedule.
After undergoing their routine physician appointments,
patients in the intervention group received pharmaceutical care
appointments during the one-year follow-up. Control group
patients continued with their usual care without pharmaceuti-
cal care service.
Patients in the intervention group had at least three phar-
maceutical care appointments of 30–60 min each. The maxi-
mum interval between returns proposed to all patients from
the Hospital Dia was four months.
The pharmaceutical care service provided for the interven-
tion group was based on the pharmacotherapy workup. The
definition of the pharmacotherapy workup employed was: a
process in which pharmacists use rational decision-making to
assess a patient’s drug-related needs, identify drug therapy
problems, develop a care plan, conduct follow-up evaluations,
and avoid safety and efficacy problems (Cipolle et al., 2004).
Pharmaceutical care activities comprised data collection
through patient interview and medical history. The clinical
pharmacist team used a standard form to collect data and
guide appointments. The team consisted of two pharmacistsPlease cite this article in press as: Molino, C.G.R.C. et al., HIV pharmaceutical care i
problems. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.201trained in pharmaceutical care and four undergraduate phar-
macist students.
The primary outcome was the drug related problem (DRP)
analysis for the intervention group, considering all drugs in use
by the patient: HAART, over the counter, and others to treat
comorbidities. DRP analysis was not performed for the con-
trol group because these patients did not receive pharmaceuti-
cal care. Two pharmacists identified and classified individually
the DRPs into four categories: (1) Indication: unnecessary
drug therapy or additional drug therapy was required to treat
or prevent a medical condition; (2) Efficacy: a drug was inef-
fective or the dosage was too low to produce the desired
response; (3) Safety: the drug caused an adverse reaction or
the dosage was too high which resulted in undesirable effects;
(4) Adherence: the patient was not able or willing to take the
drug regimen appropriately (Cipolle et al., 2004). Laboratory
tests and patient’s symptoms were used to identify and moni-
tor DRPs. Micromedex was used to check theoretical adverse
drug reaction. Adverse drug reaction was considered when a
patient reported a symptom or when there was an abnormality
in laboratory tests which could not be explained by anything
else other than adverse drug reaction.
Secondary outcomes were CD4 count and viral load eval-
uation for both groups. To analyze the influence of pharma-
ceutical care service on these parameters, we considered
their results before and after one year of pharmaceutical
care service in the intervention group. In the control group,
initial CD4 count and viral load were compared to the final
values.
After the clinical pharmacists identified the DRPs, they
developed a care plan that comprised measures to be taken
by the patient and the medical team. The care planning was
checked by two pharmacists before initiation of the interven-
tion. The pharmacist interventions were performed both orally
and with standardized written form methods. Interventions
were classified into 2 major categories: pharmacist-physician
interventions or pharmacist-patient interventions. Then, inter-
ventions were divided into 4 categories: resolve DRP, prevent
DRP, health promotion or quality of life. ‘‘Resolve DRP”:
when there was a real problem, such as lack of adherence or
presence of adverse drug reactions; ‘‘prevent DRP”: when
there was a potential problem, such as a potential drug inter-
action; ‘‘health promotion”: patient education related to
hygiene habits, disease, laboratory tests, drug storage orienta-
tion and condom use; ‘‘quality of life”: interventions related to
lifestyle (proper eating and sedentarism), drug use (illicit drugs,
tobacco and excessive intake of alcohol), and specialist refer-
ral, when necessary.
The clinical pharmacists were trained to properly classify
the DRP and intervention categories. Once a week the clinical
pharmacist team discussed all patient cases and solved issues
regarding the DRP intervention classification. If no consensus
was reached, a third pharmacist was consulted.
Antiretroviral drugs were provided to the patients by a spe-
cialized community pharmacy, also located at the University
of Campinas.
2.4. Statistical analysis
Primary and secondary outcomes were analyzed using a paired
t-test to compare the baseline values to the results found aftern primary healthcare: Improvement in CD4 count and reduction in drug-related
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as statistically significant. Graphics were made using Origin
6.0 and Microsoft Office Excel software.
2.5. Ethical approval
This study was approved by the Research Ethics Committee at
the School of Medical Sciences, University of Campinas, Bra-
zil, (protocol number 727/2009). Each patient signed a consent
form.Figure 1 Total initially selected for the study
Please cite this article in press as: Molino, C.G.R.C. et al., HIV pharmaceutical care i
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There was a total of 143 patients enrolled in this study, with
53 (37.06%) patients in the control group and 90 (62.94%)
patients in the intervention group. Among them, 57
(39.86%) were excluded with 10 (17.54%) of the patients
excluded from the control group and 47 (82.46%) from
the intervention group. At the end, 43 patients were eligible
in every arm (Fig. 1). Both groups were followed for
12 months.and the reasons for discontinuing patients.
n primary healthcare: Improvement in CD4 count and reduction in drug-related
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HIV pharmaceutical care in primary healthcare 5Each patient’s baseline characteristics are shown in Table 1.
Since the patients were paired according to their gender and
CD4 count, we found equal numbers of men (n= 28,
65.12%) and women (n= 15, 34.88%) between the groups
and similar mean basal CD4 counts, where the control group
presented with 291.09 [210.34–371.84] cells/mm3 and the inter-
vention group presented with 297.72 [208.30–387.14] cells/
mm3. The groups were similar in regard to their age, ethnicity,
and time of HIV diagnosis and treatment. Most prescribed
HAART was tenofovir, lamivudine and efavirenz in the con-
trol group (20%), and zidovudine, lamivudine and efavirenz
in the intervention group (20%). Hepatitis C was the most fre-
quent comorbidity in both groups with a 20% (n= 8.6) occur-
rence in each group.
The clinical pharmacists team performed 194 appointments
in the intervention group (mean of 4.51 [4.08–4.94] appoint-
ments per patient). A total of 202 pharmacist interventions
with 193 (95.54%) pharmacist-patient and 9 (4.46%)
pharmacist-physician interventions were proposed. A mean
of 4.7 pharmacist interventions per patient and 1.04 pharma-
cist interventions per appointment was performed.
All pharmacist-physician interventions were accepted and
aimed to resolve an identified DRP such as an additional drug
therapy required (5/9, 55.56%), unnecessary drug therapy (2/9,
22.22%), and different drug required (2/9, 22.22%).
Pharmacist-patient interventions consisted of health educa-
tion (19/193, 9.84%) and quality of life (50/193, 25.91%), to
prevent (50/193, 25.91%) and resolve DRP (74/193, 38.34%).
Pharmacist-patient interventions to prevent DRP were mostly
related to a non-adherence problem (32/50, 64%). MostTable 1 Baseline characteristics of the control and intervention gro
Characteristics Con
Age (Mean ± SD; years) 41.4
Gender
Men n (%) 28 (6
Women n (%) 15 (3
Ethnicity n (%)
Caucasian 31 (7
Mulatto 10 (2
Asian –
Black 2 (4.
HIV diagnosis (Mean [CI]; years) 7.05
HIV treatment duration (Mean [CI]; years) 5.98
Number of comorbidities (Mean ± SD) 2.70
Number of tablets per day (Mean ± SD) 9.55
Initial CD4 mean count ([CI]; cells/mm3) 291.
Initial viral load mean count ([CI]; copies/ml) 19 
Most prescribed HAART n (%)b
AZT+ 3TC+ EFV 7 (17
AZT+ 3TC+ LPV/r + TDF 2 (5.
TDF+ 3TC+ EFV 8 (20
TDF+ 3TC+ LPV/r 5 (12
AZT+ 3TC+ LPV/r 4 (10
ABC+ 3TC+ EFV 0
Other 14 (3
a Data from three patients in the control group were not considered t
(n= 40).
b Most prescribed HAART was related to n= 40 in control and inter
EFV: efavirenz. LPV/r: lopinavir/ritonavir. TDF: tenofovir.
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adjusted dosing schedules in accordance with patient’s meal
patterns (31/74, 41.89%). Fig. 2 shows how often pharmacist
interventions were performed in regard to health education,
quality of life, resolution, and prevention of DRPs.
Fig. 3 shows DRPs from the first pharmacist appointment
and after one year. Initially, 216 DRPs were identified with
5.02 [4.02–6.03] DRPs per patient. After one year of pharma-
ceutical care, 133 DRPs were found with 3.09 [2.43–3.75]
DRPs per patient. A reduction of 38.43% between the initial
and final DRPs was found and was statistically significant at
p= 0.0001.
The most common DRPs found were related to medication
safety with 138 (3.21 [2.60–3.82] DRPs per patient) found ini-
tially and 86 (2.00 [1.58–2.42] DRP per patient) one year later.
Indication DRP was the second most frequent with 50 (1.16
[0.77–1.56] DRP per patient) and 24 (0.56 [0.27–0.84] DRP
per patient) initially and after one year, respectively (Fig. 3).
Fig. 4 shows CD4 count dispersion for both groups. The
CD4 count mean presented with a significant increase in both
the intervention (p= 0.00003) and the control group
(p= 0.0078). However, the intervention group showed a mean
increase of 84% for the CD4 count in comparison with that
observed in the control group; the CD4 mean variation found
was 154.66 and 83.80 in the intervention and control group,
respectively (p= 0.4).
At baseline, both groups had a statistically similar viral
load (p= 0.10). The viral load was not significantly different
between the final and initial mean values for both groups
(p= 0.5 for the control group and p= 0.2 for the interventionup.
trol groupa Intervention group
9 ± 9.33 41.74 ± 7.93
5.12) 28 (65.12)
4.88%) 15 (34.88%)
2.09) 26 (60.47)
3.26) 13 (30.23)
1 (2.33)
65) 3 (6.98)
[5.32–8.78] 8.02 [6.06–9.98]
[4.41–7.55] 6.35 [4.70–7.99]
± 1.70 2.80 ± 1.90
± 4.70 10.25 ± 4.21
09 [210.34–371.84] 297.72 [208.30–387.14]
103 [50–42  103] 40  103 [6  103–75  103]
.50) 8 (20.00)
00) 7 (17.50)
.00) 6 (15.00)
.50) 6 (15.00)
,00) 4 (10.00)
3 (7.50)
5.00) 6 (15.00)
o HIV diagnosis, treatment time, tablets per day and comorbidities
vention group. 3TC: lamivudine. ABC: abacavir. AZT: zidovudine.
n primary healthcare: Improvement in CD4 count and reduction in drug-related
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lower than that presented by the intervention group (12  103
and 17  103 copies/mL, respectively), an approximate 4-fold
viral load reduction was found in the intervention group when
compared to the control group (23  103 for the intervention
group and 6  103 for the control group).
Regarding the viral load limit of detection (viral load
<50 copies/mL), 51.16% (n= 22) of individuals in the con-
trol group and 60.47% (n= 26) in the intervention group
began and ended the study with a viral load <50. In addition,
9.3% (n= 4) of the patients in the control group and 2.33%
(n= 1) of patients in the intervention group began the study
with a viral load <50 and after one year they presented with
a viral load >50. Finally, 3 (6.98%) patients in the interven-
tion group presented with a clinically significant increase in
their viral load compared with 11 (25.58%) patients in the con-
trol group.4. Discussion
According to Brazilian epidemiological data, the prevalence of
people living with HIV/AIDS in Brazil is 0.4% (Brazil.
Ministry of Health., 2014). Of all cases from 1980 to June
2014, the highest concentration of those affected is among
individuals aged 25–39, which comprises 54% and 50.3% of
men and women, respectively (Brazil. Ministry of Health.,
2014). Similarly, we found an age average of 41.63 [39.29–
43.96] and 41.60 [38.41–44.79] years for all men and women
enrolled in this study.Figure 2 Percentage of pharmacist interventions commonly p
Please cite this article in press as: Molino, C.G.R.C. et al., HIV pharmaceutical care i
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able to identify, resolve, and prevent a clinically significant
DRP (Viktil and Blix, 2008). Furthermore, they found evi-
dence that pharmacist interventions positively influence clini-
cal outcomes, such as improvement of drug and disease
surrogate markers, reduction of hospitalization length of stay
and re-admissions, and rates of disease events (Viktil and
Blix, 2008). Likewise, studies have shown that clinical out-
comes in HIV patients, as viral load reduction and CD4
increase, can be improved by pharmacist interventions,
(Abah et al., 2014; Nevo et al., 2015; Reis et al., 2016; Saberi
et al., 2012).
During the one-year of pharmaceutical care, most interven-
tions (95.54%) were pharmacist-patient interventions, which
resulted in a significant DRP reduction of 38.43% after one
year of pharmaceutical care. Other studies had shown that
pharmacist interventions are able to reduce DRPs, especially
problems related to medication safety, such as the presence
of adverse drug reactions for example (Blix et al., 2006;
Chisholm-Burns et al., 2010; de Maat et al., 2004; Granas
et al., 2010; Verdugo et al., 2010; Viktil and Blix, 2008). In
our study, 46 interventions intended to solve an adverse drug
reaction including a DRP drug-food interaction (n= 31)
and/or drug-drug (n= 15) interaction. After those interven-
tions, problems in regard to safety decreased from 138 to 86,
a reduction of 37.68%, indicating that the pharmacist inter-
ventions influenced the reduction of adverse reactions.
A previous study showed that 50–80% of all DRPs are pre-
dictable (Viktil and Blix, 2008) and thus pharmacist interven-
tions might resolve and prevent DRPs leading to aerformed during the study. DRPs, Drug-related problems.
n primary healthcare: Improvement in CD4 count and reduction in drug-related
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Figure 3 Mean drug related problems per patient identified in first appointment and after 1 year of pharmaceutical care. DRPs, Drug-
related problems.
Figure 4 CD4 count dispersion initially and after 1 year for intervention and control group.
HIV pharmaceutical care in primary healthcare 7significant impact in DRP reduction; however, they were not
enough to address all problems identified. Regarding other
DRPs (indication, effectiveness, and adherence) no expressive
reduction was observed as that presented for safety DRPs.
These aspects might happen due to few pharmacist-physician
interventions conducted (n= 9; 4.46%). Health team interven-
tions were proposed to reduce indication and effectiveness
DRPs, though these are the most complex interventions to
be implemented for the pharmacy staff because many patients
do not want a new drug added to their therapy regimen since
they already take a large amount of tablets daily.
Although it is well known that a clinical pharmacist must
be present at prescription time and actively participate in clin-Please cite this article in press as: Molino, C.G.R.C. et al., HIV pharmaceutical care i
problems. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.201ical case discussions in regard to the pharmacist-physician
interventions (Blix et al., 2006; Kucukarslan et al., 2003;
Viktil and Blix, 2008), our interventions were performed by
medical record entries and a verbal approach. Nonetheless,
our study had 100% of the pharmacist-physician interventions
accepted suggesting that this combined method could also be
effective and should be explored in the future.
As our data show, pharmacists should intercede with clin-
ician teams in cases of HAART intolerance and with patients
to instruct them on how to adequately take antiretroviral
drugs, encouraging therapy adherence. Knowing that barriers
to treatment adherence are complex and diverse but could
also be related to patients’ cultural attitudes and beliefsn primary healthcare: Improvement in CD4 count and reduction in drug-related
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8 C.G.R.C. Molino et al.(Bolsewicz et al., 2015) and it increases when patients have a
greater understanding about their own health (Blix et al.,
2004; de Lyra et al., 2007; de Oliveira, 2011; Strand et al.,
2004), we performed interventions to enhance patient knowl-
edge in relation to HIV/AIDS, HAART, and laboratory
tests.
In the present study, we observed a significant increase in
CD4 counts for both groups. However, the intervention group
presented with a mean CD4 increase of 154.66 cells/mm3 while
the control group had an increase of 83.8 cells/mm3
(p= 0.401) by the end of one year. Additionally, after one
year of follow-up there were 9 (20.93%) patients in the inter-
vention group and 6 (13.95%) in the control group with
CD4 counts >500 cells/mm3 and an undetectable viral load.
These data demonstrate the clinical relevance of the pharma-
cist interventions in the intervention group.
The viral load parameter did not demonstrate a statistical
difference; however, the viral load reduction was greater in
the intervention group, resulting in a mean reduction of
23.52  103 RNA copies/mL, while in the control group there
was 6.23  103 RNA copies/mL. Viral load quantification is
an important marker of HAART adherence (Bonner et al.,
2013). Previous studies had shown that the pharmacist,
through pharmaceutical care and interventions, could improve
adherence which would help with reducing the viral load
(Henderson et al., 2011; Nevo et al., 2015; Reis et al., 2016;
Saberi et al., 2012).
4.1. Strength and limitations
This study had some limitations. For instance, the pharmacist
appointments had to follow the physician’s schedule, and
therefore some data could not be analyzed due to a lack of
information in the medical charts, such as laboratory tests,
medications dose, and over-the-counter DRPs. Thus, certain
cases were not considered for analyses such as DRPs. Further-
more, due to the lack of information we could not find out the
control DRP rate. Although there was no randomization due
to the healthcare facility routine, pharmacists selected any
patients that accepted to participate in this study. After that,
the pharmacist checked whether the patient satisfied the inclu-
sion/exclusion criteria. Thus, future studies should assess
whether pharmacist interventions would have an influence on
adverse drug reaction outcomes and confirm and quantify
them by the use of specific laboratory tests.5. Conclusion
The results of this study indicate that pharmacist interven-
tions positively influenced the patients’ clinical outcomes.
Pharmacist appointments enabled identification, prevention,
and solving of drug related problems, especially those related
to drug safety. Lastly, pharmacist interventions improved
adherence and increased HAART effectiveness as suggested
by the higher elevation in the CD4 count and the viral load
reduction seen in the intervention group in comparison with
the control group.
We suggest governments and healthcare managers should
encourage the use of pharmaceutical care as a public health
service, particularly by HIV patient assistance programs.Please cite this article in press as: Molino, C.G.R.C. et al., HIV pharmaceutical care i
problems. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.201Funding
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